Cavalier Investments LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cavalier Investments LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,519 shares of the biopharmaceutical company’s stock after purchasing an additional 138 shares during the period. Cavalier Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $2,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of REGN. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $28,000. Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $933.02 on Monday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $1,088.44 and a 200-day simple moving average of $1,041.27. The company has a market cap of $102.81 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.79 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Barclays dropped their price objective on Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,101.00.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.